Analyst consensus rating
ProQR Therapeutics Analyst Rating: none
Direct answer
ProQR Therapeutics's consensus rating is none.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $8.22.
Forecast evidence checked September 5, 2026.
Get free ProQR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.07
- Average price target
- $8.22
- High price target
- $12.00
- Low price target
- $3.00
- Low target gap
- +44.9%
- Target upside
- +297.2%
- High target gap
- +479.7%
- Target range width
- 434.8%
- Consensus rating
- none
- Analysts
- 9
- Evidence date
- September 5, 2026
- Valid through
- September 12, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ProQR Therapeutics?
ProQR Therapeutics has a verified none consensus. The same dataset has an average price target of $8.22.
How far are ProQR Therapeutics's low and high targets from the recorded price?
The low target implies +44.9%, while the high target implies +479.7%.
How many analysts are included in ProQR Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is ProQR Therapeutics's target upside or downside calculated?
The average target of $8.22 is divided by the recorded price of $2.07, then one is subtracted to produce +297.2%. This does not guarantee a future return.
When was ProQR Therapeutics's analyst forecast verified?
The data was verified on 2026-09-05. The dataset is valid through 2026-09-12.